ClinicalTrials.gg
CompletedNCT05447637Updated Jul 7, 2022

PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients

An observational study in Prostate Cancer, sponsored by Invitae Corporation. Completed at 19 sites in United States. Open to male participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-07-07.

Sponsored by Invitae Corporation · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years to 90 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,597 studies in Prostatic Neoplasms with a site in United States — 605 open to participants now, 974 under way, 100 of them phase 3. Prostatic Neoplasms · United States.

Enrollment
94th of 478
1,000 · median 158
Started
2019
with 159 others
Observational
483 of 3,597
100 open now
Registered
2,897th of 3,597
by date

Among the 3,597 studies in Prostatic Neoplasms with a site in United States, this one is the 94th largest by enrollment of the 478 observational ones that give a count, is one of 160 that started in 2019, is one of 483 observational ones, and was the 2,897th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

605 of the 3,597 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

600 more — sign in →

All 605 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 90 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,597 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This registry is for men who have prostate cancer and have had multigene panel hereditary testing. The registry will gather data on genetic testing results and how that information may change physician treatment or follow up recommendations. It will also gather data on the patient's experience with genetic testing, through a post-test survey to be completed 60-90days after results have been received and discussed with their provider.

Read the detailed description

This registry will enroll men with prostate cancer who have done multi-gene testing for their cancer. Patients will be enrolled into two cohorts, one for individuals who meet current NCCN testing guidelines, and one for individuals who do not meet current NCCN guidelines.

The main goal of this Registry is to assess whether nationally developed guidelines used to select patients for hereditary testing are adequate to identify all patients with prostate cancer who may benefit from testing. Patients will completed a post-test survey regarding their testing experience and clinicians will be asked to provide additional medical records review information via the Clinician Report Form.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Men who have a diagnosis of prostate cancer who have not previously undergone testing for multi-gene hereditary cancer risk.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men ages 18-90 who have been prescribed genetic testing as part of their clinical care
  • Have prostate cancer at any stage, either actively under treatment or being followed who either: 1. meet NCCN criteria for testing or 2. do not meet NCCN criteria for testing
  • Patients who are naive to clinical genetic testing for BRCA1/BRCA2 (single gene panel testing)

Exclusion criteria

Exclusion Criteria:

  • Mental or cognitive impairment that interferes with ability to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (actual)
Target follow-up
6 Months
Patient registry
Yes
Biospecimen retention
None retained

Groups and cohorts

  • Individuals who meet NCCN Testing Criteria

    Diagnostic Test: Invitae multi-cancer gene panel

  • Individuals who do not meet NCCN Testing Criteria

    Diagnostic Test: Invitae multi-cancer gene panel

Interventions

  • Diagnostic testInvitae multi-cancer gene panel

    Invitae's multi-cancer panel tests for 84 genes associated with hereditary cancer risk.

06

What researchers measure

Primary outcomes

  1. Diagnostic yield of pathogenic and likely pathogenic genes in the patient population

    Identify the diagnostic yield of pathogenic/likely pathogenic variants in known cancer syndrome genes in patients with prostate cancer, using the Invitae 84 gene multi-cancer panel. These rates will be compared between the two cohorts.

    Time frame: to be assessed at baseline only

Secondary outcomes

  1. Evaluate the sensitivity of current NCCN criteria for germline genetic testing for identifying prostate cancer patients that have pathogenic/likely pathogenic variants

    Compare rates of pathogenic / likely pathogenic variants found in both cohorts after testing using the Invitae 84 gene multi cancer panel.

    Time frame: at baseline only

  2. Evaluate the impact of genetic test results on clinical management decisions

    Post-Test surveys for patients and the clinician report form will assess whether changes to clinical management were made as a result of the test results.

    Time frame: 60-90 days post test results received.

07

Study locations

19 sites
  • Genesis Healthcare Partners
    San Diego, California 92123, United States
  • Invitae
    San Francisco, California 94103, United States
  • Department of Bioengineering and Therapeutic Sciences, University of California San Francisco
    San Francisco, California 94158, United States
  • Volunteer Faculty, University of California San Francisco
    San Francisco, California 94158, United States
  • Colorado Urology
    Lakewood, Colorado 80228, United States
  • Advanced Urology Institute
    Saint Petersburg, Florida 33710, United States
  • Florida Urology Partners
    Tampa, Florida 33606, United States
  • TGH Cancer Institute
    Tampa, Florida 33606, United States
  • North Georgia Urology
    Dalton, Georgia 30720, United States
  • Associated Urological Specialists
    Chicago Ridge, Illinois 60415, United States
  • University Urology Associates of New Jersey
    Hamilton, New Jersey 08690, United States
  • Perlmutter Cancer Center, NYU Langone Health, New York
    New York, New York 10016, United States
  • Associated Medical Professionals
    Syracuse, New York 13210, United States
  • MidLantic Urology
    Bala-Cynwyd, Pennsylvania 19004, United States
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
  • Urology Associates, P.C.
    Nashville, Tennessee 37211, United States
  • Urology Partners
    Arlington, Texas 76017, United States
  • Urology Austin
    Austin, Texas 78759, United States
  • Urosurgery Houston
    Houston, Texas 77002, United States
08

References and documents

Individual participant data

Plan to share: No — No plan to share IPD at this time.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Jul 2021, 20 months.

Of 109 industry-sponsored observational studies under Prostatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 65. This study's 20 months is below that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2022
First posted
Jul 7, 2022
StartActual
Nov 1, 2019
Primary completionActual
Jul 1, 2021
CompletionActual
May 31, 2022
Last update
Jul 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05447637
Lead sponsor
Invitae Corporation
Responsible party
Sponsor
First posted
Jul 7, 2022
Start date
Nov 1, 2019
Primary completion
Jul 1, 2021
Completion
May 31, 2022
Last update
Jul 7, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion